| Indicators | Browse All

Jasper Therapeutics, Inc. (JSPR)

Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
0.61 USD +0.03 (4.901%) ⇧ (July 13, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 3:10 a.m. EDT

The investment case for Jasper Therapeutics has collapsed under the weight of its own history and current reality. The stock is a textbook value trap: despite trading at a fraction of its book value, the company has lost 96.58% of its value over the last five years, with the most recent annual drop being catastrophic at -82.49%. This is not a temporary correction; it is a structural implosion driven by deteriorating fundamentals, evidenced by massive negative free cash flow and a balance sheet that cannot sustain operations without external capital. The recent news of the company weighing options to sell assets or wind down confirms that the core business is no longer viable. While the analyst consensus suggests a target price nine times higher than the current level, such valuations are irrelevant for a biotech firm with no revenue and a path to profitability that appears blocked. The options market has spoken clearly, with heavy put buying acting as a hedge against total loss. There is no catalyst here to reverse the trend, and the risk of permanent capital loss remains extreme.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.216468
MSTL0.345609
AutoETS0.358219
AutoARIMA0.379905

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 28%
H-stat 17.98
Ljung-Box p 0.000
Jarque-Bera p 0.088
Excess Kurtosis -1.59
Attribute Value
Sector Healthcare
Debt to Equity Ratio 22.265
Market Cap 17,027,160
Forward P/E -0.24
Beta 3.07
Previous Name Amplitude Healthcare Acquisition Corporation
Website https://jaspertx.com

As of July 11, 2026, 3:10 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across nearly all expirations, with deep out-of-the-money puts showing massive volume relative to calls. The implied volatility skew is inverted, with OTM puts trading at premiums while OTM calls are deeply discounted, indicating a market consensus that the probability of a further collapse outweighs any chance of a recovery.


Info Dump

Attribute Value
52 Week Change -0.832853
Address1 2,200 Bridge Pkwy
Address2 Suite 102
All Time High 188.8
All Time Low 0.315
Ask 0.767
Ask Size 2
Audit Risk 9
Average Analyst Rating 2.4 - Buy
Average Daily Volume10 Day 638,090
Average Daily Volume3 Month 501,054
Average Volume 501,054
Average Volume10Days 638,090
Beta 3.074
Bid 0.4705
Bid Size 2
Board Risk 10
Book Value 0.121
City Redwood City
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 6
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.6079
Current Ratio 2.256
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 0.68
Day Low 0.58
Debt To Equity 22.265
Display Name Jasper Therapeutics
Earnings Timestamp 1,778,788,800
Earnings Timestamp End 1,786,651,200
Earnings Timestamp Start 1,786,651,200
Ebitda -69,935,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.052
Enterprise Value 3,632,266
Eps Current Year -2.41
Eps Forward -2.56
Eps Trailing Twelve Months -2.71
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.66528
Fifty Day Average Change -0.05737996
Fifty Day Average Change Percent -0.086249344
Fifty Two Week Change Percent -83.2853
Fifty Two Week High 3.53
Fifty Two Week High Change -2.9221
Fifty Two Week High Change Percent -0.8277904
Fifty Two Week Low 0.315
Fifty Two Week Low Change 0.29290003
Fifty Two Week Low Change Percent 0.92984134
Fifty Two Week Range 0.315 - 3.53
Financial Currency USD
First Trade Date Milliseconds 1,578,666,600,000
Float Shares 23,583,680
Forward Eps -2.56
Forward P E -0.23746096
Free Cashflow -42,125,124
Full Exchange Name NasdaqCM
Full Time Employees 22
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.0119
Held Percent Institutions 0.60607
Implied Shares Outstanding 28,009,802
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,704,326,400
Last Split Factor 1:10
Long Business Summary Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Long Name Jasper Therapeutics, Inc.
Market us_market
Market Cap 17,027,160
Market State PRE
Max Age 86,400
Message Board Id finmb_647336542
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-13
Net Income To Common -55,734,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 16,231,680
Number Of Analyst Opinions 3
Open 0.6
Operating Cashflow -68,867,000
Operating Margins 0.0
Overall Risk 8
Payout Ratio 0.0
Phone 650 549 1400
Prev Name Amplitude Healthcare Acquisition Corporation
Previous Close 0.5795
Price Eps Current Year -0.25224066
Price Hint 4
Price To Book 5.0239673
Profit Margins 0.0
Quick Ratio 1.572
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key buy
Recommendation Mean 2.4
Region US
Regular Market Change 0.0284
Regular Market Change Percent 4.90078
Regular Market Day High 0.68
Regular Market Day Low 0.58
Regular Market Day Range 0.58 - 0.68
Regular Market Open 0.6
Regular Market Previous Close 0.5795
Regular Market Price 0.6079
Regular Market Time 1,783,972,801
Regular Market Volume 1,343,348
Return On Assets -1.1223
Return On Equity -2.44212
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 6
Shares Outstanding 28,009,802
Shares Percent Shares Out 0.0608
Shares Short 1,703,161
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 2,246,874
Short Name Jasper Therapeutics, Inc.
Short Percent Of Float 0.0622
Short Ratio 2.11
Source Interval 15
State CA
Symbol JSPR
Target High Price 20.0
Target Low Price 1.5
Target Mean Price 9.16667
Target Median Price 6.0
Total Cash 14,144,000
Total Cash Per Share 0.505
Total Debt 757,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.71
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.387385
Two Hundred Day Average Change -0.779485
Two Hundred Day Average Change Percent -0.56183755
Type Disp Equity
Volume 1,343,348
Website https://jaspertx.com
Zip 94,065